Recordati Industria Chimica e Farmaceutica SpA AAQS 2024
Recordati Industria Chimica e Farmaceutica SpA AAQS
10
Ticker
REC.MI
ISIN
IT0003828271
WKN
A0EABR
Recordati Industria Chimica e Farmaceutica SpA ima trenutni AAQS od 10. Visoki AAQS može se smatrati pozitivnim pokazateljem da se poduzeće uspješno razvija. Investitori mogu očekivati da je poduzeće na dobrom putu da ostvaruje dobit. S druge strane, važno je usporediti AAQS dionice Recordati Industria Chimica e Farmaceutica SpA s ostvarenim dobitima i drugim poduzećima iste industrije. Visoki AAQS nije apsolutna garancija za pozitivnu budućnost. Samo tako možemo dobiti potpunu sliku o performansi poduzeća. Da bi bolje procijenili razvoj poduzeća, važno je usporediti AAQS s drugim poduzećima iste industrije. Generalno, investitori bi uvijek trebali razmatrati AAQS poduzeća u kontekstu s drugim financijskim pokazateljima poput dobiti, EBIT-a, Cash Flow-a i drugih kako bi donijeli obrazloženu investicijsku odluku.
Recordati Industria Chimica e Farmaceutica SpA Aktienanalyse
Što radi Recordati Industria Chimica e Farmaceutica SpA?
Recordati Industria Chimica e Farmaceutica SpA is an Italian pharmaceutical company based in Milan. The company was founded in 1926 by Giovanni Recordati and now has branches in many countries worldwide. Recordati's business model is based on the development, production, and marketing of drugs for various therapeutic areas. The company focuses particularly on therapy areas such as cardiology, urology, gastroenterology, pneumology, and hematology. Recordati operates in four business areas: Innovative Medicines, OTC Medicines, Generics, and Licensed Products. In the area of innovative medicines, the company specializes in the development of new active substances for the treatment of rare diseases. In the OTC Medicines area, Recordati specializes in the manufacture and marketing of over-the-counter drugs used to treat mild to moderate complaints. The generics area includes the production and marketing of generic products with the aim of influencing price development in the market. In the Licensed Products area, Recordati collaborates with other companies and takes over the marketing of their products in certain regions. Some of Recordati's best-known products include Cariprazine (an antipsychotic), Urolith (a preventive treatment for kidney stones), Zanipress (a treatment for hypertension), and Fokusin (a treatment for benign prostatic hyperplasia). Recordati is also committed to improving access to life-saving medications worldwide. The company engages in collaborations with international organizations such as the Global Alliance for TB Drug Development and supports the WHO's "Target Product Profiles" initiative. In 2019, Recordati Industria Chimica e Farmaceutica SpA achieved sales of around 1.4 billion euros in over 90 countries. The company employs about 4,200 people worldwide, including approximately 500 researchers and developers. In terms of future direction, Recordati sees continued high potential for growth and expansion, particularly through targeted investments in research and development. The company relies on close cooperation with other partners within the industry and the exploration of new markets and therapeutic areas. Recordati Industria Chimica e Farmaceutica SpA ist eines der beliebtesten Unternehmen auf Eulerpool.com.Česta pitanja o Recordati Industria Chimica e Farmaceutica SpA dionici
Aktiensparpläne nude atraktivnu mogućnost za investitore za dugoročno stvaranje imovine. Jedna od glavnih prednosti je tzv. efekt prosječenja troškova: investirajući redovito fiksni iznos u dionice ili dioničke fondove, automatski se kupuje više udjela kada su cijene niske, a manje kada su visoke. To može dovesti do povoljnijeg prosječnog cijene po udjelu tijekom vremena. Osim toga, Aktiensparpläne omogućavaju i malim investitorima pristup skupim dionicama, jer mogu sudjelovati već s malim iznosima. Redovita investicija također promiče discipliniranu strategiju ulaganja i pomaže izbjeći emocionalne odluke, poput impulzivne kupnje ili prodaje. Pored toga, investitori profitiraju od potencijalnog povećanja vrijednosti dionica kao i od isplata dividendi koje mogu biti reinvestirane, što pojačava učinak kamatnog kamata i time rast uloženog kapitala.
Andere Kennzahlen von Recordati Industria Chimica e Farmaceutica SpA
Naša analiza dionica Recordati Industria Chimica e Farmaceutica SpA Prihod uključuje važne financijske pokazatelje kao što su prihod, dobit, P/E omjer, P/S omjer, EBIT, kao i informacije o dividendi. Također, razmatramo aspekte poput dionica, tržišne kapitalizacije, dugova, vlastitog kapitala i obveza Recordati Industria Chimica e Farmaceutica SpA Prihod. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama nudimo opsežne analize:
- Recordati Industria Chimica e Farmaceutica SpA Prihod
- Recordati Industria Chimica e Farmaceutica SpA Dobit
- Recordati Industria Chimica e Farmaceutica SpA KGV
- Recordati Industria Chimica e Farmaceutica SpA KUV
- Recordati Industria Chimica e Farmaceutica SpA EBIT
- Recordati Industria Chimica e Farmaceutica SpA Dividenda
- Recordati Industria Chimica e Farmaceutica SpA Dionice
- Recordati Industria Chimica e Farmaceutica SpA Tržišna kapitalizacija
- Recordati Industria Chimica e Farmaceutica SpA Dugovanje
- Recordati Industria Chimica e Farmaceutica SpA Obveze
- Recordati Industria Chimica e Farmaceutica SpA Temeljni kapital
- Recordati Industria Chimica e Farmaceutica SpA AAQS
- Recordati Industria Chimica e Farmaceutica SpA zaposlenici
- Recordati Industria Chimica e Farmaceutica SpA ROE
- Recordati Industria Chimica e Farmaceutica SpA ROA
- Recordati Industria Chimica e Farmaceutica SpA ROCE